Patients with Diabetes Not at Highest Risk for Contrast-Induced Nephrotoxicity

Article

New study challenges common belief and finds patients with a history of renal disease, hypertension or heart disease were more likely to suffer renal insufficiency.

Patients with diabetes are not the highest risk group for developing contrast-induced nephrotoxicity as commonly believed, say researchers from Northwestern Memorial Hospital-Northwestern University in Chicago.

Instead, patients with a history of renal disease, hypertension or heart disease were more likely to suffer renal insufficiency, putting them at greater risk, according to their study, designed to find which group of patients at highest risk for contrast-induced nephrotoxicity. The results were presented at the American Roentgen Ray Society Annual Meeting this week in Vancouver, Canada.

Researchers evaluated 2,404 patients who underwent an estimated glomerular filtration rate (eGFR) test immediately before undergoing a CT examination. This allowed the researchers to see if the traditional risk factors accurately predicted reduced renal function.

“Patients with history of renal disease, hypertension, and heart disease had significantly higher odds of having abnormal eGFR,” said Vahid Yaghmai, MD, one of the study’s authors. This was not found in patients with a history of diabetes.

Yaghmai suggested eGFR be performed on the patients who indicate, via survey, that they are at high risk of such nephrotoxicity. “Measuring eGFR right before the CT scan can help us more accurately determine at-risk patients,” he said.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.